M2951

( DrugBank: - / KEGG DRUG: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	28
46	Malignant rheumatoid arthritis	8

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	5

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 10 of 28 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004980-36-RO (EUCTR)	29/06/2021	27/04/2022	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ...
2	EUCTR2019-004980-36-SI (EUCTR)	18/03/2021	06/10/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ...
3	EUCTR2019-004980-36-NO (EUCTR)	16/12/2020	03/07/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Not Recruiting	Female: yes Male: yes	930	Phase 3	Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ...
4	EUCTR2019-004972-20-FI (EUCTR)	06/11/2020	04/09/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Serbia;United States;Hong Kong;Taiwan;Estonia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia ...
5	EUCTR2019-004972-20-DE (EUCTR)	05/11/2020	11/05/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Serbia;United States;Taiwan;Hong Kong;Estonia;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia ...
6	EUCTR2019-004980-36-LT (EUCTR)	22/10/2020	25/05/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ...
7	EUCTR2019-004980-36-BG (EUCTR)	12/10/2020	19/06/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ...
8	EUCTR2019-004972-20-CZ (EUCTR)	01/10/2020	05/06/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Serbia;United States;Hong Kong;Taiwan;Estonia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia ...
9	EUCTR2019-004980-36-DE (EUCTR)	29/09/2020	08/09/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Germany;Puerto Rico;Russian Federation;Singapore;United States;Malaysia;Thailand;Portugal;Saudi Arab ...
10	EUCTR2019-004972-20-BG (EUCTR)	23/09/2020	19/06/2020	Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ...	Merck Healthcare KGaA	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	930	Phase 3	Serbia;United States;Hong Kong;Taiwan;Estonia;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia ...

First Previous1 2 3Next Last

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 8 of 8 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-000384-32-BG (EUCTR)	02/11/2017	12/07/2017	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Saf ...	Rheumatoid Arthritis MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: Evobrutinib Other descriptive name: ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	363	Phase 2	United States;Serbia;Ukraine;Chile;Russian Federation;Colombia;Czech Republic;Mexico;Argentina;Brazi ...
2	EUCTR2017-000384-32-CZ (EUCTR)	26/09/2017	26/07/2017	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Saf ...	Rheumatoid Arthritis MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: Evobrutinib Other descriptive name: ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	363	Phase 2	Serbia;United States;Ukraine;Russian Federation;Chile;Colombia;Czech Republic;Mexico;Argentina;Brazi ...
3	NCT03233230 (ClinicalTrials.gov)	September 18, 2017	25/7/2017	Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis	A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Saf ...	Rheumatoid Arthritis	Drug: M2591 25 mg QD;Drug: M2951 75 mg QD;Drug: M2951 50 mg BID;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Completed	18 Years	75 Years	All	390	Phase 2	United States;Argentina;Bulgaria;Chile;Colombia;Czechia;Mexico;Poland;Russian Federation;Serbia;Sout ...
4	EUCTR2016-000064-42-BG (EUCTR)	11/08/2016	28/06/2016	Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Rheumatoid Arthritis MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: M2951 Product Code: M2951 INN or Proposed INN: N/A Other descriptive name: M2951 Product N ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	United States;Hungary;Estonia;Czech Republic;Slovakia;Poland;Ukraine;Romania;Bulgaria
5	EUCTR2016-000064-42-HU (EUCTR)	05/08/2016	06/06/2016	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Rheumatoid Arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: M2951 Product Code: M2951 INN or Proposed INN: N/A Other descriptive name: M2951	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	Estonia;Czech Republic;Hungary;Slovakia;Poland;Ukraine;Romania;South Africa;Bulgaria
6	NCT02784106 (ClinicalTrials.gov)	July 31, 2016	24/5/2016	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Rheumatoid Arthritis	Drug: Placebo;Drug: M2951	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Completed	18 Years	75 Years	All	65	Phase 2	United States;Germany
7	EUCTR2016-000064-42-SK (EUCTR)	27/07/2016	03/05/2016	Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Rheumatoid Arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: M2951 Product Code: M2951 INN or Proposed INN: N/A Other descriptive name: M2951	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	Hungary;Estonia;Czech Republic;Slovakia;Poland;Ukraine;Romania;South Africa;Bulgaria
8	EUCTR2016-000064-42-CZ (EUCTR)	21/06/2016	08/06/2016	Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Rheumatoid Arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: M2951 Product Code: M2951 INN or Proposed INN: N/A Other descriptive name: M2951	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 2	Hungary;Estonia;Czech Republic;Slovakia;Poland;Ukraine;Romania;South Africa;Bulgaria

First Previous1Next Last

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

trials per page:

Showing 1 to 5 of 5 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002950-19-DE (EUCTR)	19/06/2017	12/04/2017	A Phase II Study of M2951 in SLE	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety a ...	Systemic Lupus Erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: Evobrutinib Other descriptive name: ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	468	Phase 2	United States;Philippines;Taiwan;Russian Federation;Chile;Colombia;Italy;Mexico;Mauritius;Argentina; ...
2	EUCTR2016-002950-19-BG (EUCTR)	27/04/2017	27/03/2017	A Phase II Study of M2951 in SLE	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety a ...	Systemic Lupus Erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: Evobrutinib Other descriptive name: ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	468	Phase 2	United States;Philippines;Taiwan;Russian Federation;Chile;Colombia;Italy;Mexico;Mauritius;Argentina; ...
3	EUCTR2016-002950-19-PL (EUCTR)	25/04/2017	28/03/2017	A Phase II Study of M2951 in SLE	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety a ...	Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: Evobrutinib Other descriptive name: ...	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	468	Phase 2	United States;Philippines;Taiwan;Russian Federation;Chile;Colombia;Italy;Mexico;Mauritius;Argentina; ...
4	JPRN-JapicCTI-183957	20/1/2017	14/05/2018	A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety a ...	Systemic Lupus Erythematosus	Intervention name : M2951(Other Name: Evobrutinib) INN of the intervention : - Dosage And administrati ...	Merck Biopharma Co., Ltd	Merck KGaA	complete	18	75	BOTH	480	Phase 2	Japan, Asia except Japan, North America, South America, Europe, Africa
5	NCT02975336 (ClinicalTrials.gov)	January 4, 2017	23/11/2016	A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety a ...	Systemic Lupus Erythematosus	Drug: Placebo;Drug: M2951	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Terminated	18 Years	75 Years	All	480	Phase 2	United States;Argentina;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Maur ...

First Previous1Next Last